Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Update on Interim Dividend Timetable

9 Nov 2021 16:36

RNS Number : 8493R
Alliance Pharma PLC
09 November 2021
 

For immediate release

9 November 2021

 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Update on interim dividend timetable

 

In the Group's interim results for the six months ended 30 June 2021 announced on 21 September 2021, Alliance stated that its 2021 interim dividend payment of 0.563p per share (the "Interim Dividend") would be paid on 7 January 2022 to shareholders on the register on 24 December 2021.

 

Alliance would now like to update the market that it has brought forward the record date for the Interim Dividend to 17 December 2021, with the payment date remaining as 7 January 2022 as previously announced.

 

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams

 

Corporate Broking: Patrick Robb

 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVBLBDBSXGDGBC
Date   Source Headline
23rd Nov 20165:45 pmRNSExercise of Share Options
17th Nov 20165:05 pmRNSNotification of Major Interest in Shares
17th Nov 201610:40 amRNSExercise of Share Options
28th Oct 20165:13 pmRNSShare Options
28th Oct 20167:00 amRNSAppointment of Deputy CEO
5th Oct 20166:00 pmRNSExercise of Share Options
23rd Sep 20167:01 amRNSExercise of Share Options
23rd Sep 20167:00 amRNSDirector Dealings
14th Sep 20167:00 amRNSInterim Results
13th Sep 20167:00 amRNSNew Agreement for Diclectin in Europe
18th Aug 20167:00 amRNSInterim Results Analyst Meeting - Change of Time
8th Aug 20165:00 pmRNSExercise of Share Options
2nd Aug 20167:00 amRNSNotification of Interim Results
26th Jul 20167:00 amRNSExercise of Share Options
19th Jul 20167:00 amRNSHalf Year Trading Update
12th Jul 20167:00 amRNSNotification of Half Year Trading Update
25th May 201611:15 amRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
24th May 20167:00 amRNSExercise of Share Options
5th May 20161:30 pmRNSDirector Shareholding
3rd May 20167:00 amRNSExercise of Share Options
28th Apr 20167:00 amRNSAnnual Report and AGM Notice
7th Apr 20167:00 amRNSPreliminary Results
18th Mar 20167:00 amRNSNotification of Preliminary Results
3rd Mar 20167:00 amRNSHardman & Co Research Report
5th Feb 20163:57 pmRNSExercise of Share Options
22nd Jan 20163:45 pmRNSExercise of Share Options
21st Jan 20167:00 amRNSPre-Close Trading Update
12th Jan 20162:34 pmRNSNotification of Major Interest in Shares
7th Jan 20161:56 pmRNSNotification of Major Interest in Shares
23rd Dec 201512:02 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
22nd Dec 20154:40 pmRNSDirector Shareholding
18th Dec 20155:15 pmRNSNotification of Major Interest in Shares
18th Dec 20154:20 pmRNSNotification of Major Interest in Shares
18th Dec 20153:54 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th Dec 20153:39 pmRNSNotification of Major Interest in Shares
17th Dec 20153:13 pmRNSNotification of Major Interest in Shares
17th Dec 20159:00 amRNSCompletion of Acquisition and Placing
14th Dec 20154:00 pmRNSResult of General Meeting
8th Dec 20155:41 pmRNSNotification of Major Interest in Shares
7th Dec 20157:00 amRNSShare Options
3rd Dec 20152:03 pmRNSPlacing Update: Exercise of Broker's Option
2nd Dec 20158:00 amRNSSchedule 1 - Alliance Pharma Plc
26th Nov 20154:35 pmRNSInterim Dividend Timetable
26th Nov 20157:00 amRNSProposed Acquisition
23rd Nov 20154:00 pmRNSDirectorate Change
5th Nov 20157:00 amRNSSettlement Agreement
10th Sep 20157:00 amRNSInterim Dividend Timetable - Record Date
9th Sep 20157:00 amRNSInterim Results
2nd Sep 20156:01 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.